Relationship between endocrine resistance and the periods of adjuvant endocrine treatment for hormone receptor-positive, HER2-negative breast cancer
| Autor: | Yukiko Miyamura, Shunji Kamigaki, Jun Yamamura, Yukihiko Hahimot, Hironobu Manabe, Yoshifumi Komoike, Toshikazu Ito, Junya Fujita, Yumiko Tanaka, Hiroki Osato, Wataru Shinzaki |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty Receptor ErbB-2 medicine.medical_treatment Endocrine resistance Breast Neoplasms Young Adult Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Endocrine system Longitudinal Studies First Recurrence Aged Retrospective Studies Aged 80 and over business.industry HER2 negative General Medicine Middle Aged medicine.disease Hormones Progression-Free Survival Receptors Estrogen Drug Resistance Neoplasm Hormone receptor Female Receptors Progesterone business Adjuvant Hormone |
| Zdroj: | Breast Disease. 41:109-114 |
| ISSN: | 1558-1551 0888-6008 |
| Popis: | BACKGROUND: Current guidelines define primary and secondary endocrine resistance according to the periods of adjuvant endocrine therapy (adj-ET); however, the relationship between adj-ET period and endocrine resistance remains unclear. OBJECTIVE: We examined progression-free survival (PFS) after primary ET for recurrent hormone receptor-positive/HER2-negative breast cancer, and evaluated the relationship between endocrine resistance and the periods of adj-ET. METHODS: We assessed PFS among 183 patients who received ET as primary treatment for the first recurrence, according to the period of adj-ET (adj-ET < 1 year, 1–2 years, ≥2 years, and completion). RESULTS: Patients who relapsed during the first year of adj-ET had the significantly shortest PFS. PFS did not significantly differ between patients who relapsed at 1–2 years of adj-ET and patients who relapsed while on adj-ET but after the first 2 years. CONCLUSIONS: Relapse at 1–2 years after adj-ET initiation might be better classified as secondary endocrine resistance rather than primary endocrine resistance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|